Novo Nordisk sales soar amid demand for obesity treatments

Novo is currently treating about 500,000 US patients

The Wegovy injections suppress appetite. File picture

Novo Nordisk sales surged in the third quarter and double-digit growth should carry into 2024 driven by burgeoning demand for its obesity and diabetes blockbusters.

Revenue jumped 38% to 59 billion kroner (€8bn) excluding some items, the Danish drugmaker said, strengthening its grip on an obesity market estimated to hit $100bn (€94bn) by 2030. Operating profit also rose 47% during the period.